- Report
- September 2023
- 140 Pages
Global
From €3435EUR$3,599USD£2,878GBP
- Report
- September 2023
- 160 Pages
Global
From €3435EUR$3,599USD£2,878GBP
- Report
- August 2024
- 82 Pages
Japan
From €3340EUR$3,500USD£2,799GBP
- Report
- February 2024
- 170 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2024
- 181 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 177 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 188 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- November 2023
- 90 Pages
France
From €3340EUR$3,500USD£2,799GBP
- Report
- September 2020
- 700 Pages
Global
From €4676EUR$4,900USD£3,918GBP
- Report
- September 2022
- 83 Pages
Global
From €3340EUR$3,500USD£2,799GBP
From €114EUR$119USD£95GBP
- Book
- June 2020
- 198 Pages
- Book
- August 2023
- 224 Pages

The Tumor Microenvironment (TME) is a complex network of cells, proteins, and other molecules that interact with cancer cells and influence their behavior. It is an important factor in the development and progression of cancer, and is increasingly being studied in the context of oncology drugs.
TME research has revealed that cancer cells are not the only players in the development of cancer. The TME is composed of a variety of cell types, including immune cells, fibroblasts, and endothelial cells, as well as extracellular matrix components, cytokines, and growth factors. These components interact with cancer cells to influence their behavior, such as proliferation, invasion, and metastasis.
The TME is also an important factor in drug response. Drugs that target the TME can be used to enhance the efficacy of existing cancer therapies, as well as to develop new treatments. For example, drugs that target the TME can be used to reduce tumor-associated inflammation, which can improve the efficacy of chemotherapy and radiation therapy.
Companies in the TME market include AstraZeneca, Merck, Novartis, Pfizer, and Roche. Show Less Read more